Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
For those on the front line of the battle against malaria, news of the development of a vaccine against the parasite is an exciting development.In the 97 countries in which malaria is endemic, it ravages the economic productivity of those who can least afford it: poor people with limited access to treatment and care.In July, the European Medicines Agency approved RTS,S – a vaccine also known by its trade name, Mosquirix – for use in children 6-17 months old. The global health community has long appreciated the importance of a vaccine in reducing the disease's burden, and the World Health Organization is expected to make an announcement in November about the use of Mosquirix in countries where malaria is endemic, some 30 excruciating years after researchers at the pharmaceutical company GlaxoSmithKline began working on the vaccine.In the time it has taken to read this article, five children will have died from malaria.
FOLLOW THIS ARTICLE